Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Capital Expenditures: 2021-2024

Historic Capital Expenditures for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $157,000.

  • Amylyx Pharmaceuticals' Capital Expenditures rose 226.32% to $24,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $72,000, marking a year-over-year decrease of 85.40%. This contributed to the annual value of $157,000 for FY2024, which is 87.35% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Capital Expenditures of $157,000 as of FY2024, which was down 87.35% from $1.2 million recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Capital Expenditures high stood at $2.5 million for FY2022, and its period low was $157,000 during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Capital Expenditures had a median value of $1.2 million in 2023 and averaged $1.3 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Capital Expenditures spiked by 615.58% in 2022 and then tumbled by 87.35% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Capital Expenditures stood at $353,000 in 2021, then soared by 615.58% to $2.5 million in 2022, then tumbled by 50.87% to $1.2 million in 2023, then tumbled by 87.35% to $157,000 in 2024.